Clik here to view.
Post-QE2 Economy Skipping Biotech (BBH, XBI, CELG, GILD, AMGN, BIIB, ALXN,...
Things have changed in the last week. The mid-term elections took away the majority of the House of Representatives, and the Senate now no longer has the super-majority which could get laws passed no...
View ArticleClik here to view.
Clearing Some Air in Genzyme & HGSI (GENZ, HGSI)
Two key biotechs had a rough day on Friday and these issues will be key to focus on in the coming days. Genzyme Corporation (NASDAQ: GENZ) is showing some very concerning trends, and the first Lupus...
View ArticleVindication for Human Genome… Takeover Chatter to Resume? (HGSI, GSK)
Human Genome Sciences Inc. (NASDAQ: HGSI) has some vindication for its BENLYSTA as a treatment for lupus. The company announced that it and partner GlaxoSmithkline plc (NYSE: GSK) received FDA panel...
View ArticleFDA Brings More Doubt Over BENLYSTA Against Lupus (HGSI, GSK)
More problems for those suffering from lupus! The FDA has decided to delay its review of the proposed lupus treatment BENLYSTA. Human Genome Sciences, Inc. (NASDAQ: HGSI) and GlaxoSmithKline PLC...
View ArticleA Very Cautious Case Against Human Genome (HGSI, GSK)
It was just earlier this week in a broad call that Human Genome Sciences Inc. (NASDAQ: HGSI) saw a very positive research call in a sector initiation as its stock was initiated with an “Outperform” and...
View ArticleClik here to view.
Bullish 2011 Outlook For Human Genome (HGSI)
Human Genome Sciences, Inc. (NASDAQ: HGSO) has received a positive research call from an analyst targeting upside in the shares. Gleacher & Co. initiated coverage on the company with a BUY rating...
View ArticleClik here to view.
Big Biotechs With The Most Upside for 2011 (AMGN, GILD, CELG, HGSI, DNDN,...
Bioheath Investor is creating some ongoing outlook pieces as 2010 ends so we have an outline of what to expect for 2011. We have already given the “Best of Big Biotech in 2010″ and now we want to...
View ArticleBenlysta Approval Cheat Sheet: What You Need to Know (HGSI, GSK)
It is official… The FDA has approved Benlysta as the first new drug regimen for systemic lupus in over 50 years. Human Genome Sciences, Inc. (NASDAQ: HGSI) and partner GlaxoSmithKline plc (NYSE: GSK)...
View ArticleOdds-Making on a Human Genome Sciences Acquisition (HGSI, GSK, BIIB, MRK)
Human Genome Sciences Inc. (NASDAQ: HGSI) is surging on reports that GlaxoSmithKline PLC (NYSE: GSK) could be set to make a $25.00 per share offer to acquire the company. The report surfaced in the...
View ArticleCan Human Genome Really Double Its Stock Price? (HGSI)
At the end of December, we usually review the biotech sector to see which stocks have the most upside for the year ahead. The basis of the “implied upside” is the consensus mean estimate from Thomson...
View Article
